A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

Sponsor: ALX Oncology Inc.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05002127

Patient View

This Phase 2/3 study evaluates Evorpacept with trastuzumab, ramucirumab, and paclitaxel in patients with metastatic HER2+ gastric/GEJ adenocarcinoma post-HER2 therapy and chemotherapy. Enrolling 450 adults, it requires adequate organ function and excludes those with CNS metastases or prior anti-CD47/SIRPα or ramucirumab treatment. Interventions are administered intravenously.

Patient Parameters

Program Overview

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Description

This is a randomized phase 2 (open-label) / 3 (double-blind), international, multi-center study of patients with metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or 3rd-line). Approximately 450 adult patients are expected to be enrolled in the study across both phases.

Eligibility Criteria

Inclusion Criteria

  • HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
  • Adequate Bone Marrow Function.
  • Adequate Renal & Liver Function.
  • Adequate Performance Status

Exclusion Criteria

  • Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
  • Prior treatment with any anti-CD47 or anti-SIRPα agent.
  • Prior treatment with ramucirumab.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.